Isoray Press Release Archive
In 2023 Isoray merged with Viewpoint Molecular Targeting. Access the archived Press Releases from Isoray.
Initial Results From First Patient Dosed With Perspective Therapeutics’ Lead Drug VMT-α-NET Presented at The Treatment of Neuroendocrine Disorders at the 2023 PET/RTRC Annual Workshop Scientific Session
The result from first patient dosed with 212Pb-VMT-α-NET in India on a compassionate use basis showed favorable responses after the first dose.
The initial response was measured by a somatostatin imaging agent 68Ga-DOTANOC and demonstrated encouraging results after a single low dose of 212Pb-VMT-α-NET.
Perspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022
“The fourth quarter represented a transformational period leading up to the completed merger between Isoray and Viewpoint Molecular Targeting. In the Company’s core brachytherapy business lack of orders from our largest customer and post-COVID recovery efforts resulted in a sales decline.
Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.
New tagline: “Treating cancers from the inside out”
New corporate website https://www.perspectivetherapeutics.com
New NYSE American stock ticker symbol to be CATX, effective February 21, 2023…..
Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine
Outgoing Isoray CEO Lori Woods said, “This merger represents an important milestone for Isoray. The merger with Viewpoint Molecular Targeting demonstrates our commitment to build on our shared belief of treating cancers from the inside out while providing personalized targeted treatment options for cancer patients…
The stockholders approved Proposal One which amends the Company’s Certificate of Incorporation to increase the total number of authorized shares of Common Stock to 750,000,000 shares….
The Board of Directors, as well as leading proxy advisory firms Institutional Shareholder Services (“ISS”) and Glass, Lewis & Co., recommend stockholders vote in support of Proposal 1…..
The Board of Directors, as well as leading proxy advisory firms Institutional Shareholder Services (“ISS”) and Glass, Lewis & Co., recommend stockholders vote in support of Proposal 1.
Isoray CEO Lori Woods said the pending merger signifies a watershed moment in the evolution of the company. “The pending merger represents an exciting transformational opportunity for Isoray and all our stakeholders….
To listen to the conference call, please dial (877) 545-0320. For callers outside the U.S., please dial (973) 528-0002.
Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT
The presentation will provide an overview of Viewpoint’s pipeline along with a review of data presented at this year’s European Association of Nuclear Medicine conference which concludes on October 19 in Barcelona, Spain.
Isoray Announces Transformational Merger and Fourth Quarter and Full-Year Fiscal Year End 2022 Financial Results
Under the terms of the agreement, a newly formed wholly owned subsidiary of Isoray will merge with and into Viewpoint, with Viewpoint becoming a wholly owned subsidiary of Isoray.
To listen to the conference call, please dial 888-506-0062. For callers outside the U.S., please dial 973-528-0011.